cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2021-2939cardiovascular-2939Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯCLINIC AND PHARMACOTHERAPYИспользование прямых пероральных антикоагулянтов при проведении электрической кардиоверсииDirect oral anticoagulants for electrical cardioversionhttps://orcid.org/0000-0002-0923-735XВоловченкоА. Н.VolovchenkoA. N.

Алексей Николаевич Воловченко — кандидат медицинских наук, зав. кардиологическим отделением клиники кардиологии УКБ № 1.

Москва. Тел.: +7 (926) 027-97-39

Moscow

dr.volovchenko@mail.ruhttps://orcid.org/0000-0002-0276-7374АндреевД. А.AndreevD. A.

Денис Анатольевич Андреев — доктор медицинских наук, профессор, зав. кафедрой кардиологии, функциональной и ультразвуковой диагностики, директор клиники кардиологии УКБ № 1.

Москва

Moscow

dennan@mail.ruhttps://orcid.org/0000-0003-3541-6041МеситскаяД. Ф.MesitskayaD. F.

Динара Фератовна Меситская — кандидат медицинских наук, зав. учебной частью кафедры кардиологии, функциональной и ультразвуковой диагностики.

Москва

Moscow

aranid980@gmail.comФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)I.M. Sechenov First Moscow State Medical University20211707202120429392939Copyright © Воловченко А.Н., Андреев Д.А., Меситская Д.Ф., 20212021Воловченко А.Н., Андреев Д.А., Меситская Д.Ф.Volovchenko A.N., Andreev D.A., Mesitskaya D.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2939

В статье рассмотрены вопросы антикоагулянтной подготовки к проведению плановой электрической кардиоверсии у больных с персистирующей формой фибрилляции предсердий. Предложены обновленные схемы подготовки к электрической кардиоверсии и обсуждается возможность использования прямых пероральных антикоагулянтов с этой целью.

The article discusses the issues of anticoagulant preparation for elective electrical cardioversion in patients with persistent atrial fibrillation. Updated preparation regimens for electrical cardioversion are proposed, as well as the potential of using direct oral anticoagulants for this purpose is discussed.

фибрилляция предсердийэлектрическая кардиоверсияантикоагулянтная терапияпрямые пероральные антикоагулянтыatrial fibrillationelectrical cardioversionanticoagulant therapydirect oral anticoagulantsСтатья подготовлена при финансовой поддержке ООО “Пфайзер Инновации”. В статье выражена позиция авторов, которая может отличаться от позиции компанииThe article was prepared with the financial support of Pfizer Innovations LLC. The article expresses the position of the authors, which may differ from the position of the companyReferencesRoy D, Talajic M, Nattel S, et al.; for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77. doi:10.1056/NEJMoa0708789.Roy D, Talajic M, Nattel S, et al.; for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77. doi:10.1056/NEJMoa0708789.Wyse DG, Waldo AL, DiMarco JP, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. doi:10.1056/NEJMoa021328.Wyse DG, Waldo AL, DiMarco JP, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. doi:10.1056/NEJMoa021328.Van Gelder I, HagensV, Bosker H, et al. Comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40. doi:10.1056/NEJMoa021375.Van Gelder I, HagensV, Bosker H, et al. Comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40. doi:10.1056/NEJMoa021375.Kirchhof P, Camm AJ, Goette A, et al.; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-16. doi:10.1056/NEJMoa2019422.Kirchhof P, Camm AJ, Goette A, et al.; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-16. doi:10.1056/NEJMoa2019422.Ha AC, Breithardt G, Camm AJ, et al. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF). Circ Cardiovasc Qual Outcomes 2014;7(6):896-904. doi:10.1161/hcq.0000000000000011.Ha AC, Breithardt G, Camm AJ, et al. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF). Circ Cardiovasc Qual Outcomes 2014;7(6):896-904. doi:10.1161/hcq.0000000000000011.Rochlani YM, Shah NN, Pothineni NV, Paydak H. Utilization and Predictors of Electrical Cardioversion in Patients Hospitalized for Atrial Fibrillation. Cardiol Res Pract. 2016;2016:8956020.doi:10.1155/2016/8956020.Rochlani YM, Shah NN, Pothineni NV, Paydak H. Utilization and Predictors of Electrical Cardioversion in Patients Hospitalized for Atrial Fibrillation. Cardiol Res Pract. 2016;2016:8956020.doi:10.1155/2016/8956020.Новикова Н. А., Воловченко А. Н. Использование прямых пероральных антикоагулянтов при подготовке к электрической кардиоверсии. Вестник аритмологии. 2017;(88):18-24.Novikova NA, Volovchenko AN. Direct oral anticoagulants during preparation to electric cardioversion. Journal of Arrhythmology. 2017;(88):18-24. (In Russ.)Arias MA, Casares-Medrano J, Pachón M, Puchol A. Silent embolism after electrical cardioversion of atrial fibrillation: what does brain magnetic resonance imaging provide? Rev Esp Cardiol. 2012;65(5):489. doi:10.1016/j.recesp.2011.12.010.Arias MA, Casares-Medrano J, Pachón M, Puchol A. Silent embolism after electrical cardioversion of atrial fibrillation: what does brain magnetic resonance imaging provide? Rev Esp Cardiol. 2012;65(5):489. doi:10.1016/j.recesp.2011.12.010.Airaksinen KE, Gronberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (FinnishCardioVersion) study. J Am Coll Cardiol. 2013;62:1187-92. doi:10.1016/j.jacc.2013.04.089.Airaksinen KE, Gronberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (FinnishCardioVersion) study. J Am Coll Cardiol. 2013;62:1187-92. doi:10.1016/j.jacc.2013.04.089.Hansen ML, Jepsen RM, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015;17(1):18-23. doi:10.1093/europace/euu189.Hansen ML, Jepsen RM, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015;17(1):18-23. doi:10.1093/europace/euu189.Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411-20. doi:10.1056/NEJM200105103441901.Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411-20. doi:10.1056/NEJM200105103441901.Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210.Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210.Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131-6. doi:10.1161/CIRCULATIONAHA.110.977546.Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131-6. doi:10.1161/CIRCULATIONAHA.110.977546.Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998-2006. doi:10.1016/j.jacc.2013.02.025.Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998-2006. doi:10.1016/j.jacc.2013.02.025.Flaker G, Lopes RD, Al Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082-7. doi:10.1016/j.jacc.2013.09.062.Flaker G, Lopes RD, Al Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082-7. doi:10.1016/j.jacc.2013.09.062.Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. doi:10.1093/eurheartj/ehu367.Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. doi:10.1093/eurheartj/ehu367.Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959-71. doi:10.1093/eurheartj/ehy148.Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959-71. doi:10.1093/eurheartj/ehy148.Инструкция по медицинскому применению препарата Эликвис®. Рег. уд. No: ЛП-002007-220817. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3f0f386b-3c8b-4c57-a3c1-10e223ae76a7&t=.Instructions for medical use: Eliquis®. Reg. ud. No: LP-002007-220817. (In Russ.) http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3f0f386b-3c8b-4c57-a3c1-10e223ae76a7&t=.Telles-Garcia N, Dahal K, Kocherla C, et al. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol. 2018; 268:143-8. doi:10.1016/j.ijcard.2018.04.034.Telles-Garcia N, Dahal K, Kocherla C, et al. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol. 2018; 268:143-8. doi:10.1016/j.ijcard.2018.04.034.Gibson CM, Basto AN, Howard ML. Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence. Ann Pharmacother. 2018;52(3):277-84. doi:10.1177/1060028017737095.Gibson CM, Basto AN, Howard ML. Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence. Ann Pharmacother. 2018;52(3):277-84. doi:10.1177/1060028017737095.Itäinen S, Lehto M, Vasankari T, et al. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace. 2018;20:565-8. doi:10.1093/europace/eux116.Itäinen S, Lehto M, Vasankari T, et al. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace. 2018;20:565-8. doi:10.1093/europace/eux116.Russo V, Rago A, Proietti R, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017;8(2):67-75. doi:10.1177/2042098616673990.Russo V, Rago A, Proietti R, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017;8(2):67-75. doi:10.1177/2042098616673990.Rago A, Papa AA, Cassese A, et al. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study. Am J Cardiovasc Drugs. 2019;19:421-7. doi:10.1007/s40256-019-00341-9.Rago A, Papa AA, Cassese A, et al. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study. Am J Cardiovasc Drugs. 2019;19:421-7. doi:10.1007/s40256-019-00341-9.Russo V, Rago A, Papa AA, et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2018;45:206-12. doi:10.1007/s11239-017-1599-5.Russo V, Rago A, Papa AA, et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2018;45:206-12. doi:10.1007/s11239-017-1599-5.Russo V, Di Napoli L, Bianchi V, et al. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short-term rivaroxaban administration: The MonaldiVert real life experience. Int J Cardiol. 2016;224:454-5. doi:10.1016/j.ijcard.2016.09.022.Russo V, Di Napoli L, Bianchi V, et al. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short-term rivaroxaban administration: The MonaldiVert real life experience. Int J Cardiol. 2016;224:454-5. doi:10.1016/j.ijcard.2016.09.022.Coleman CM, Khalaf S, Mould S, et al. Novel Oral Anticoagulants for 641 DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. Pacing Clin Electrophysiol. 2015;38:731-7. doi:10.1111/pace.12618.Coleman CM, Khalaf S, Mould S, et al. Novel Oral Anticoagulants for 641 DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. Pacing Clin Electrophysiol. 2015;38:731-7. doi:10.1111/pace.12618.Frederiksen AS, Albertsen, AE, Christesen AMS, et al. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin. Europace. 2018;20:1078-85. doi:10.1093/europace/eux188.Frederiksen AS, Albertsen, AE, Christesen AMS, et al. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin. Europace. 2018;20:1078-85. doi:10.1093/europace/eux188.Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol. 2001;37:691-704. doi:10.1016/s0735-1097(00)01178-5.Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol. 2001;37:691-704. doi:10.1016/s0735-1097(00)01178-5.Stabile G, Russo V, Rapacciuolo A, et al. Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: A multi center registry. Int J Cardiol. 2015;184:283-4. doi:10.1016/j.ijcard.2015.02.075.Stabile G, Russo V, Rapacciuolo A, et al. Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: A multi center registry. Int J Cardiol. 2015;184:283-4. doi:10.1016/j.ijcard.2015.02.075.Hohnloser SH, Cappato R, Ezekowitz MD, et al. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial. Europace. 2016;18(2):184-90. doi:10.1093/europace/euv294.Hohnloser SH, Cappato R, Ezekowitz MD, et al. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial. Europace. 2016;18(2):184-90. doi:10.1093/europace/euv294.Russo V, Rago A, Papa, AA, et al. Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study. Minerva Cardioangiol. 2018;66:1-5. doi:10.23736/S0026-4725.17.04500-5.Russo V, Rago A, Papa, AA, et al. Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study. Minerva Cardioangiol. 2018;66:1-5. doi:10.23736/S0026-4725.17.04500-5.Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. Eur Heart J Cardiovasc Pharmacother. 2017;3:147-50. doi:10.1093/ehjcvp/pvx003.Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. Eur Heart J Cardiovasc Pharmacother. 2017;3:147-50. doi:10.1093/ehjcvp/pvx003.Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of NonVitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021:euab065. doi:10.1093/europace/euab065.Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of NonVitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021:euab065. doi:10.1093/europace/euab065.

The authors declare that there are no conflicts of interest present.